



Supplementary Material

Article Title: Efficacy and Safety of the $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia:

Results From a Phase 2b Randomized Controlled Study in Smokers

Author(s): George M. Haig, PharmD, MBAa,*; Deli Wang, MD, PhDa; Jun Zhao, PhD; Ahmed A. Othman, PhDa; and Earle E. Bain, MDa

DOI Number: <https://doi.org/10.4088/JCP.16m11162>

List of Supplementary Material for the article

1. [eTable 1](#) MCCB Neurocognitive Composite Score Repeated-measures Analysis (ITT)
2. [eTable 2](#) Other Secondary Measures, Analysis of Covariance (ITT Population)
3. [eTable 3](#) Summary of Adverse Events

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1. MCCB Neurocognitive Composite Score Repeated-measures Analysis (ITT)

	N	Mean (SD)	LS Mean (SE) of Change	Difference from Placebo		
				LS Mean (SE)	90% CI	<i>P</i> value ^a
Baseline						
Placebo	44	32.57 (10.33)	—	—	—	—
ABT-126 25 mg	49	28.55 (12.32)	—	—	—	—
ABT-126 75 mg	46	26.02 (10.81)	—	—	—	—
Change to week 6						
Placebo	43	0.65 (5.28)	0.88 (0.80)	—	—	—
ABT-126 25 mg	48	0.54 (4.91)	0.60 (0.74)	−0.28 (1.07)	−2.06, 1.50	0.602
ABT-126 75 mg	46	0.74 (4.96)	0.78 (0.76)	−0.10 (1.10)	−1.93, 1.73	0.537
Change to week 12						
Placebo	39	1.36 (5.72)	1.42 (0.88)	—	—	—
ABT-126 25 mg	45	0.38 (5.44)	0.28 (0.81)	−1.14 (1.19)	−3.11, 0.83	0.830
ABT-126 75 mg	41	0.56 (4.63)	0.41 (0.85)	−1.01 (1.22)	−3.04, 1.01	0.796

^aOne-sided *P* value.

Abbreviations: CI = confidence interval, ITT = intent to treat, LS = least squares, MCCB = MATRICS Consensus Cognitive Battery, SD = standard deviation, SE = standard error.

Supplementary eTable 2. Other Secondary Measures, Analysis of Covariance (ITT Population)

Assessment	Placebo	ABT-126 25 mg	ABT-126 75 mg
Cigarettes/day in past week	N = 47	N = 51	N = 46
Baseline mean (SD)	14.26 (8.94)	16.05 (10.57)	14.26 (6.93)
LS mean change to final (SE), <i>P</i>	1.62 (1.38)	0.90 (1.28), 0.666	0.38 (1.39), 0.763
MTCQ-SF	N = 45	N = 51	N = 46
Baseline mean (SD)	45.00 (9.97)	47.31 (11.37)	46.46 (11.41)
LS mean change to final (SE), <i>P</i>	1.31 (1.69)	-0.24 (1.54), 0.775	-1.45 (1.67), 0.905
No. days drinking in past week^a	N = 14	N = 12	N = 18
Baseline mean (SD)	0.29 (0.61)	0.58 (1.00)	0.56 (0.86)
LS mean change to final (SE), <i>P</i>	0.51 (0.37)	-0.03 (0.36), 0.827	0.22 (0.38), 0.724
Average No. drinks/day in past week^a	N = 14	N = 12	N = 18
Baseline mean (SD)	0.29 (0.61)	0.67 (1.07)	0.47 (0.70)
LS mean change to final (SE), <i>P</i>	0.62 (0.35)	0.35 (0.34), 0.696	0.71 (0.36), 0.422

Note: *P* values (italicized) are one-sided specified a priori.

^aCurrent drinkers in the ITT.

Abbreviations: ITT = intent to treat, LS = least squares, MTCQ-SF = Modified Tobacco Craving Questionnaire–Short Form, SD = standard deviation, SE = standard error.

Supplementary eTable 3. Summary of Adverse Events

	Placebo N=50	ABT-126 25 mg N=52	ABT-126 75 mg N=51
Any AE	25 (50.0)	27 (51.9)	24 (47.1)
Discontinued due to an AE	4 (8.0)	0	4 (7.8)
Severe AE	1 (2.0)	0	2 (3.9)
Serious AE	2 (4.0)	0	1 (2.0)
AEs reported by $\geq 3\%$ of ABT-126–treated subjects ^a by MedDRA preferred term			
Constipation	0	2 (3.8)	4 (7.8)
Weight increased	2 (4.0)	3 (5.8)	3 (5.9)
Nasopharyngitis	4 (8.0)	2 (3.8)	2 (3.9)

Note: Values are presented as n (%).

^aBoth ABT-126 treatment groups combined.

Abbreviations: AE = adverse event, MedDRA = Medical Dictionary for Regulatory Activities.